Abstract:It is well accepted that the balance of immunity between effector and regulatory T cells determines the outcome of autoimmune and chronic inflammatory diseases. Concerning the topic of ‘Regulatory and Effector T Cells’ as published in this issue of Journal of Molecular Cell Biology, several investigators have provided important new information. T-helper 1 (Th1) and Th2 cells represent the classical type of Th or effector cells. However, recent studies have also identified several new cell subsets of Th cells, including IL-9-producing T (Th9), IL-17-producing T (Th17), IL-22-producing T (Th22), and T follicular helper (Tfh) cells, extending the Th cell structure. Given their crucial role in the pathogenesis of autoimmune and inflammatory diseases, Th17 cells have received much attention. They mainly express IL-17A, but co-express IL-17B, IL-17E (IL-25), IL-17F, and IL-22. IL-26 is produced by human but not mouse Th17 cells. IL-17A is significantly more potent in initiating signaling and causing autoimmune responses than other cytokines produced by these cells. The differentiation of mouse Th17 cells needs the combination of IL-6 and transforming growth factor-beta (TGF-b) (Bettelli et al., 2006), although IL-6or TGF-b-independent pathways may also contribute to Th17 cell differentiation. The role of TGF-b in human Th17 cell differentiation is still controversial. Of note, the IL-21 and IL-1 signal pathways seem to be important in initiating Th17 cell development. IL-21 and IL-23 are also known to sustain and expand Th17 cells. Dr Ryffel’s group provides an updated account of the differentiation and function of Th17 cells, particularly during lung injury and inflammatory disease. They demonstrated that lung injury or allergen exposure leads to NLPR3 activation, with formation of the NLPR3 inflammasome complex and caspase-1 activation resulting in mature IL-1b, which may elicit IL-17 production. Traditionally, asthma is elicited by Th2 cells. It is still unclear whether Th17 cells work independent or together with Th2 cells in the development of asthma. They suggest that Th17 cells promote asthma through modulation of Th2 cells. In fact, IL-17E or IL-25, another IL-17 member, can induce Th2 cytokines and promote allergy. It is also possible that IL-17 regulates allergic responses independent of Th2 cells but Th2 cells promote asthma through Th17 cells since IL-4 does regulate IL-17 levels. It has been widely accepted that Tregs are critically involved in immune tolerance and homeostasis. Although this concept was suggested in early 1970s, it was resuscitated in 1990s when thymus-derived CD4+CD25+ cells were identified as natural Tregs (nTregs) (Sakaguchi et al., 1995). While Foxp3 has been identified as a unique marker and functional transcription factor for these cells, studies on Tregs have been greatly accelerated. As Treg frequency and functional alterations are associated with many autoimmune diseases, the manipulation of these cells provides a promising treatment possibility for autoimmune diseases. In addition, use of Tregs may be valuable in the prevention of graft rejection of organ transplantation and graft-versus-host disease (GVHD). Dr Bluestone’s group further provides information on the potential use of these cells in the clinic. They reported that by 2011, three clinical trials have been undertaken to test the safety of Treg therapy in GVHD, and all have demonstrated promising safety and efficacy profiles. Compelling evidence from animal models and human patients demonstrates that tolerance to allogeneic transplant can be achieved by reconditioning the immune system, so that troublesome global immunosuppression can be minimized or completely stopped. They emphasize that a sound trial design should harness the tolerogenic potential of Tregs while minimizing risks. One potential risk with Treg therapy is that these cells can purportedly exhibit some measure of plasticity. Since little is known about the appropriate doses of Tregs in humans, initial trials should be safety-centered evaluating effect of increasing

Regulatory T cells control the transition from acute into chronic inflammation in glucose-6-phosphate isomerase-induced arthritis

Regulatory T Cells Control Epitope Spreading in Autoimmune Arthritis Independent of Cytotoxic T‐lymphocyte Antigen‐4

In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice

Therapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis

TGF-β-induced CD4+ Regulatory T Cells but Not Ntregs Ameliorate Autoimmune Arthritis by Shifting the Balance Between Tregs and Th17 Cells in Vivo (179.14)

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis

Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase

Self-reactive T Cells Induce and Perpetuate Chronic Relapsing Arthritis

Combination treatment with fingolimod and a pathogenic antigen prevents relapse of glucose‐6‐phosphate isomerase peptide‐induced arthritis

Regulatory T cells control type 1-driven immunopathology restraining GM-CSF-producing helper T cells

Redox Regulation of a New Autoimmune Mouse Model, Glucose-6-phosphate Isomerase Peptide Induced Arthritis in Mice (BA12P.108)

A glucose-6-phosphate isomerase peptide induces T and B cell-dependent chronic arthritis in C57BL/10 mice: arthritis without reactive oxygen species and complement.

Contribution of Inflammation and Bone Destruction to Pain in Arthritis: A Study in Murine Glucose‐6‐Phosphate Isomerase–Induced Arthritis

A novel inhibitory pathway of synovial inflammation exerted by glucocorticoids and tumor necrosis factor inhibitors via lymphocyte activation gene-3 up-regulation: an ex-vivo study

Local inhibition of TGF-β1 signaling improves Th17/Treg balance but not joint pathology during experimental arthritis

CTLA-4 Expressed by FOXP3+ Regulatory T Cells Prevents Inflammatory Tissue Attack and Not T-cell Priming in Arthritis.

Characterization of an Expanded IL-10-Producing-Suppressive T Cell Population Associated with Immune Tolerance

Emerging Topics and New Perspectives on Regulatory and Effector T Cells.

Defining Epigenome Responses in T-cell Arthritogenicity: in Search for Effectors of Autoimmunity. (P4076)

Restoring Oxidant Signaling Suppresses Proarthritogenic T Cell Effector Functions in Rheumatoid Arthritis.